Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of eltrombopag in thrombocytopenic subjects with hepatitis C virus infection eligible for peginterferon plus ribavirin
2008-000660-17Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eltrombopag in hepatitis C virus infection and Thrombocytopenia, sponsored by GSK. Primary endpoint: Safety and tolerability of eltrombopag. Started Jun 2009; status: completed.
02
Drugs
eltrombopag
03
Conditions
hepatitis C virus infectionThrombocytopenia
Beyond the preview
Go deeper on 2008-000660-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000660-17.